ClearPoint: MAK Capital reports 6.1% stake
ClearPoint Neuro, Inc. Schedule 13G shows that MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman beneficially own 1,729,611 shares of Common Stock, representing 6.1% of the class as of 03/13/2026.
Rhea-AI Filing Summary
ClearPoint Neuro, Inc. Schedule 13G shows that MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman beneficially own 1,729,611 shares of Common Stock, representing 6.1% of the class as of 03/13/2026. The filing reports shared voting and dispositive power over those shares. The excerpt cites 28,423,308 shares outstanding as of October 27, 2025 per the issuer's Form 10-Q.
Positive
- None.
Negative
- None.
Insights
MAK group holds a notable passive stake with shared control.
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman report beneficial ownership of 1,729,611 shares (6.1%) with shared voting and dispositive power as of 03/13/2026. The filing is a standard Schedule 13G disclosure for large passive holders.
Cash‑flow treatment and any planned transactions are not stated in the excerpt; subsequent filings would show changes. The holder's shared control indicates decisions may involve multiple reporting entities; monitor future ownership filings for any change in voting or disposition patterns.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does MAK Capital report in ClearPoint Neuro (CLPT)?
Who are the reporting persons on the Schedule 13G for CLPT?
Does the Schedule 13G indicate sole voting or dispositive power?
AI-generated analysis. How Rhea-AI works. Not financial advice.